^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    22h
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2d
    JKART-1: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Jul 2027 --> Nov 2025
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    2d
    Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    cyclophosphamide • melphalan • fludarabine IV • Inrebic (fedratinib)
    2d
    RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Henan Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    cyclophosphamide • fludarabine IV
    2d
    MCC-21622: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=3, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV • PRGN-3007
    2d
    QUADvance: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=178, Not yet recruiting, AvenCell Therapeutics, Inc.
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia. (PubMed, Cell Cycle)
    Cytarabine (ara-C) and fludarabine (F-ara-A) are key drugs in leukaemia treatment. Mechanistically, IMPDHi depleted allosteric SAMHD1 activators GTP and dGTP, thereby increasing active triphosphate metabolites in SAMHD1-proficient, but not SAMHD1-deficient, cells. Our findings suggest that the addition of IMPDHi to ara-C and F-ara-A may have therapeutic benefits in some AML cases.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    cytarabine • fludarabine IV
    3d
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    3d
    Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=244, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Venclexta (venetoclax) • melphalan • fludarabine IV • busulfan
    3d
    Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma. (PubMed, Sci Rep)
    Subsequently, we validated our findings using the STAT1 inhibitor fludarabine or the NK cell-depleting agent Asialo GM1. Furthermore, combination therapy remodeled the tumor microenvironment by reducing CA IX (hypoxia marker), CD31 (angiogenesis marker), and α-SMA (stromal activation marker) expression (p < 0.05). Apatinib enhances the efficacy and responsiveness of PD-1 inhibition via the STAT1/NK axis, while the combination therapy remodels the tumor microenvironment to potentiate anti-tumor effects.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD31 (Platelet and endothelial cell adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    AiTan (rivoceranib) • fludarabine IV
    3d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=20, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV